Please assess the completion status of the following clinical trial:

Trial Title: A Study of Nimotuzumab in Combination With External Radiotherapy in Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
1. Patients must have histologically or cytologically confirmed non-small cell lung cancer.~2. Patients must be suitable for palliative radiation therapy as per institutional standards.~3. Stage IIB, III or IV (patients off steroids with treated, stable brain metastases are eligible).~4. Patients may be symptomatic or asymptomatic from disease~5. Age \>18 years~6. ECOG 0-1-2~7. Patients who received previous chemotherapy are allowed~8. Haemoglobin \>9g/dL (blood transfusion to increase Hb level is acceptable)~9. Stage II/III patients must be considered unsuitable for radical (standard full dose curative intent) chemoradiation in the opinion of either the radiotherapist or medical oncologist.~10. Patients must have measurable disease in the planned radiation field.~11. Women of child-bearing potential and men must agree to use adequate contraception.~12. Ability to understand and the willingness to sign a written informed consent document~Exclusion criteria - Phase I and Phase II:~1. Patients receiving any other investigational agents~2. Previous treatment with anti-EGF-R drug(s)~3. History of allergic reactions attributed to compounds of similar chemical or biologic composition to nimotuzumab or other agents used in study.~4. Prior thoracic radiotherapy for this condition~5. Prior chemotherapy within 4 weeks of enrolment~6. Lesions not suitable for radiotherapy~7. Patients with known sero positive HIV~8. Patients with uncontrolled hypercalcemia~9. Patients with progressive or untreated brain metastases or treated brain metastases but unable to discontinue steroids~10. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, severe cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements in the opinion of the investigator~11. Pregnant or breast-feeding women~12. Any concurrent active malignancy other than non-melanoma skin cancer or carcinoma in situ of the cervix; patients with other prior malignancies are eligible providing prior malignancy cannot be clinically confused with the diagnosis of NSCLC in the opinion of the treating oncologist; in particular, there should be no evidence of current disease activity with respect to the prior malignancy~13. Life expectancy of less than 8 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 200 mg dose
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).